Lauren Dembeck, PhD, is a freelance science & medical writer. She specializes in medicine and healthcare, focusing on topics such as hematology, oncology, immunotherapy, and mental health care, among others. Her work has been featured in various publications, including Oncology Nurse Advisor, Infectious Disease Advisor, and Cancer Therapy Advisor.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Lauren Dembeck's articles predominantly cite data related to medical research, hematology, cancer treatment, and blood disorders. She appears to focus on scientific themes within the healthcare and pharmaceutical sector. Given her reliance on data-backed information, she may be interested in receiving pitches from researchers or professionals with access to new and significant datasets or those who can provide expert analysis of existing ones.
Lauren appears to have a broad international scope rather than a specific geographic focus. Her coverage seems centered around developments in medical research and treatments globally without being limited to any particular region.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Lauren Dembeck
A 10-year follow-up from the phase 3 RELEVANCE trial confirmed that first-line lenalidomide plus rituximab provides durable progression-free survival and overall survival (PFS and OS) comparable to rituximab-based immunochemotherapy (R-chemo) in patients with previously untreated advanced follicular lymphoma (FL), according to findings published in Blood.
By: Lauren Dembeck
Between 2012 and 2023, sickle cell disease (SCD) mortality increased in Colombia and was significantly higher in socioeconomically disadvantaged regions, according to findings from a nationwide population-based study published in Orphanet Journal of Rare Diseases.
By: Lauren Dembeck
High pretransplant expression of serum- and glucocorticoid-inducible kinase 1 (SGK1) is associated with an increased risk of disease progression and shorter survival after autologous stem cell transplantation (ASCT) among patients with multiple myeloma (MM), according to findings published in Biochemical Genetics.
By: Lauren Dembeck
Lauren Dembeck, PhD | Publish Date Tumor enucleation may preserve kidney function and reduce major complications compared
By: Lauren Dembeck
Lauren Dembeck, PhD | Publish Date Adding blinatumomab to consolidation and maintenance therapy significantly improves
By: Lauren Dembeck
Elevated high-sensitivity cardiac troponin I (hs-cTnI) levels are relatively common among patients with sickle cell disease (SCD) presenting to the emergency department (ED) with acute pain, but rarely indicate acute myocardial infarction (MI), according to findings published in the British Journal of Haematology.
By: Lauren Dembeck
Lauren Dembeck, PhD | Publish Date Urine tumor DNA (utDNA) testing may identify patients with high-risk non-muscle-invasive
By: Lauren Dembeck
Lauren Dembeck, PhD | Publish Date Omitting systematic biopsy after multiparametric magnetic resonance imaging (mpMRI)-targeted
Induction with CPX-351, a liposomal formulation of daunorubicin and cytarabine, resulted in inferior event-free survival (EFS) and a higher risk of relapse compared with standard daunorubicin/cytarabine (DA) among children and young adults with newly diagnosed acute myeloid leukemia (AML) without FLT3 mutations, with poorer outcomes driven largely by patients with low-risk disease, according to phase 3 findings published in the Journal of Clinical Oncology.
By: Lauren Dembeck
The new International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus genomic staging (CGS) system effectively identifies patients with newly diagnosed multiple myeloma (MM) at high risk for poor outcomes despite treatment with contemporary regimens, according to findings published in HemaSphere.
